Answers are grounded in this paper and cite their sources.
New operative techniques, novel devices and conduits, refinements in perioperative management, and the integration of hybrid, robotic, and catheter-based approaches have steadily expanded the therapeutic options available to heart teams. Many of these advances are supported by rigorous efficacy evidence and represent genuine progress for patients.1 At the same time, the real-world performance of new procedural therapies is often incompletely characterized at the time they are widely adopted. Clinical trials necessarily involve selected centres, experienced operators, and carefully specified protocols. Once an innovation diffuses into routine practice, it is applied across a much broader spectrum of institutions, surgical teams, and patient populations. For surgeons and healthcare systems, the central question therefore extends beyond whether a new procedure can work to how it performs when implemented at scale. We argue that the introduction of major procedural innovations should be accompanied by coordinated, prospective implementation trials embedded in routine care. Such an approach treats adoption not as the end-point of evidence generation, but as its starting point.
No takes yet. Share an insight, caveat, or question.
Redfors et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: